pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › TLX

TLX PDUFA Date: TLX101-Px

FDA decision (PDUFA) target 2026-09-11 · Telix Pharmaceuticals Limited · Recurrent or progressive glioma (brain cancer)

TLX run-up into the PDUFA (last ~120 days)

$11.26$6.41
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-09-11
Drug / candidateTLX101-Px
IndicationRecurrent or progressive glioma (brain cancer)
CompanyTelix Pharmaceuticals Limited
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.govNCT07100730 · recruiting

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the TLX PDUFA date?
The FDA PDUFA target date for TLX (Telix Pharmaceuticals Limited) is 2026-09-11 for TLX101-Px. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is TLX's drug TLX101-Px?
TLX101-Px is Telix Pharmaceuticals Limited's candidate under FDA review for Recurrent or progressive glioma (brain cancer).
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.